EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bi-directional metabolic reprogramming between cancer cells and T cells reshapes the anti-tumor immune response

Yajing Qiu, Yihan Xu, Xinyuan Ding, Congcong Zhao, Hongcheng Cheng, Guideng Li iD

PLOS Biology · 14.07.2025 · 23 (7) · e3003284

DOI: 10.1371/journal.pbio.3003284 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Biology, online erschienen am 14.07.2025. Verfasst von Yajing Qiu und 5 weiteren Autor:innen. Beteiligte Einrichtung: National Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medica…. Hauptthemen laut MEDLINE: Neoplasms, T-Lymphocytes. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 196 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project, National Natural Science Foundation of China, Central Research Institute Fund of the Chinese Academy of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer cells and T cells engage in dynamic crosstalk within the tumor microenvironment (TME), shaping tumor progression and anti-tumor immunity. While cancer cells reprogram metabolism to support growth and immune evasion, T cells must adapt their metabolic states to maintain effector functions. Tumor-driven metabolic perturbations, such as nutrient depletion and accumulation of immunosuppressive metabolites, profoundly impair T cell function and fate. Conversely, metabolically reprogrammed T cells can modulate the TME and influence tumor growth. This reciprocal metabolic crosstalk represents both metabolic competition and intercellular communication, offering promising therapeutic targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsT-LymphocytesAnimalsHumansCell CommunicationCellular ReprogrammingMetabolic ReprogrammingTumor Microenvironment

Autor:innen und Institutionen

  • National Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, Jiangsu, China.
  • Key Laboratory of Synthetic Biology Regulatory Elements, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, Jiangsu, China.
  • Department of Pharmacy, Medical Science University and Suzhou Technology China Innovation Center, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School of Nanjing Medical U…

ORCID-Profile: Guideng Li

Förderung

  • Noncommunicable Chronic Diseases-National Science and Technology Major Project
  • National Natural Science Foundation of China
  • Central Research Institute Fund of the Chinese Academy of Medical Sciences
  • Innovation Fund for Medical Sciences (CIFMS)
  • Gusu Innovation and Entrepreneurship Talent Program
  • Basic Research Program of Jiangsu
  • Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences
  • CAMS Innovation Fund for Medical Sciences

Zitieren

APA

Qiu, Y., Xu, Y., Ding, X., Zhao, C., Cheng, H., & Li, G. (2025). Bi-directional metabolic reprogramming between cancer cells and T cells reshapes the anti-tumor immune response. PLOS Biology, 23(7), e3003284. https://doi.org/10.1371/journal.pbio.3003284

Vancouver

Qiu Y, Xu Y, Ding X, Zhao C, Cheng H, Li G. Bi-directional metabolic reprogramming between cancer cells and T cells reshapes the anti-tumor immune response. PLOS Biology. 2025;23(7):e3003284. doi:10.1371/journal.pbio.3003284

BibTeX
@article{Qiu2025,
  author = {Qiu, Yajing and Xu, Yihan and Ding, Xinyuan and Zhao, Congcong and Cheng, Hongcheng and Li, Guideng},
  title = {Bi-directional metabolic reprogramming between cancer cells and T cells reshapes the anti-tumor immune response},
  journal = {PLOS Biology},
  year = {2025},
  volume = {23},
  number = {7},
  pages = {e3003284},
  doi = {10.1371/journal.pbio.3003284}
}
Kostenlos starten →